EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

After 25 Years of Experience: What Do We Know About Escitalopram?

Gözde Çolak iD, Ali Saffet Gönül iD

Psychiatry and Clinical Psychopharmacology · 12.08.2026 · 36 (4) · 451-461

DOI: 10.65801/pcp.3553 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Psychiatry and Clinical Psychopharmacology, online erschienen am 12.08.2026. Verfasst von Gözde Çolak und 1 weiteren Autor:innen. Beteiligte Einrichtung: SoCAT Lab, Department of Psychiatry, School of Medicine, Ege University, Izmir, Türkiye. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Escitalopram, the S-enantiomer of racemic citalopram, is one of the most widely prescribed selective serotonin reuptake inhibitors (SSRIs) for the treatment of depressive and anxiety disorders. Owing to its high selectivity for the serotonin transporter (SERT) and its unique allosteric binding properties, escitalopram demonstrates pharmacological characteristics that distinguish it from other SSRIs. This narrative review provides an up-to-date evaluation of escitalopram, focusing on its mechanism of action, pharmacokinetic profile, clinical efficacy, tolerability, and safety. Evidence from randomized controlled trials and meta-analyses indicates that escitalopram produces significant antidepressant and anxiolytic effects, with symptom improvement often observed within the first one to two weeks of treatment. Neuroimaging studies further support its therapeutic activity by demonstrating dose-dependent SERT occupancy and normalization of fronto-limbic network dysfunction associated with mood regulation. In comparative studies, escitalopram yields favorable response and remission rates and exhibits better acceptability and tolerability relative to other antidepressant agents. Its pharmacokinetic properties—including predictable absorption, linear dose–concentration relationships, and limited cytochrome P450 interactions—contribute to its suitability for long-term use and polypharmacy. Escitalopram is generally well tolerated, with most adverse effects being mild and transient. Although sexual dysfunction, QT interval prolongation, and serotonin syndrome remain clinical considerations, its overall safety profile compares favorably with that of other SSRIs. In conclusion, current evidence supports escitalopram as a first-line pharmacological treatment for major depressive disorder and anxiety disorders. Its pharmacological specificity, consistent clinical efficacy, and favorable tolerability profile reinforce its central role in contemporary psychiatric treatment strategies.

Schlagwörter

Stichwörter der Autor:innen

antidepressantsescitalopramgeneralized anxiety disordermajor depressive disorderserotonin transporter

Autor:innen und Institutionen

  • SoCAT Lab, Department of Psychiatry, School of Medicine, Ege University, Izmir, Türkiye.

ORCID-Profile: Gözde Çolak, Ali Saffet Gönül

Zitieren

APA

Çolak, G., & Gönül, A. S. (2026). After 25 Years of Experience: What Do We Know About Escitalopram?. Psychiatry and Clinical Psychopharmacology, 36(4), 451-461. https://doi.org/10.65801/pcp.3553

Vancouver

Çolak G, Gönül AS. After 25 Years of Experience: What Do We Know About Escitalopram?. Psychiatry and Clinical Psychopharmacology. 2026;36(4):451-461. doi:10.65801/pcp.3553

BibTeX
@article{olak2026,
  author = {Çolak, Gözde and Gönül, Ali Saffet},
  title = {After 25 Years of Experience: What Do We Know About Escitalopram?},
  journal = {Psychiatry and Clinical Psychopharmacology},
  year = {2026},
  volume = {36},
  number = {4},
  pages = {451--461},
  doi = {10.65801/pcp.3553}
}
Kostenlos starten →